Zalups R K, Lash L H
Division of Basic Medical Sciences, Mercer University School of Medicine, Macon, GA 31207, USA.
Drug Metab Dispos. 1997 Apr;25(4):516-23.
The primary aim of the present study was to evaluate the effects of different means of depleting glutathione (GSH) in the kidneys and liver on the renal and hepatic accumulation and disposition of a nontoxic dose of inorganic mercury. Renal and hepatic disposition of mercury were evaluated 1 hr after the intravenous administration of a 0.5 mumol/kg dose of mercuric chloride in control rats and rats pretreated with acivicin, buthionine sulfoximine (BSO), or diethylmaleate (DEM). Pretreatment with acivicin or DEM caused significant decreases in the net renal accumulation of mercury during the first hour after the injection of mercuric chloride. The primary effects of these two pretreatments occurred in the renal cortex, although pretreatment with DEM also caused significant decreases in the concentration of mercury in the outer stripe of the outer medulla. Despite the fact that pretreatment with BSO caused a reduction in the renal content of GSH, comparable with that caused by DEM, pretreatment with BSO had no significant effect on the renal disposition of mercury. Pretreatment with acivicin, BSO, or DEM also caused significant decrease in measurable reduced GSH, with BSO and DEM having the most pronounced effects. Injection of the nontoxic dose of mercuric chloride after pretreatment with acivicin resulted in slightly, but significantly, decreased hepatic content of mercury. Interestingly, pretreatment with BSO or DEM actually caused significant increases in the hepatic content of mercury 1 hr after the injection of mercuric chloride. We postulate that this effect was due to a diminished ability of hepatocytes to export mercuric conjugates of GSH out into either the bile or blood. The results of this study indicate that depletion of renal GSH by conjugation reactions between GSH and DEM leads to an acute reduction in the renal accumulation of inorganic mercury. However, the results also indicate that depletion of renal levels of GSH by inhibition of GSH synthesis does not affect acutely the ability of the kidneys to accumulate inorganic mercury. Thus, it seems that factors in addition to intracellular GSH status play an important role in the renal accumulation/retention of inorganic mercury.
本研究的主要目的是评估肾脏和肝脏中不同方式消耗谷胱甘肽(GSH)对无毒剂量无机汞在肾脏和肝脏中的蓄积及处置的影响。在对照大鼠以及用阿西维辛、丁硫氨酸亚砜胺(BSO)或马来酸二乙酯(DEM)预处理的大鼠静脉注射0.5 μmol/kg剂量的氯化汞1小时后,评估汞在肾脏和肝脏中的处置情况。用阿西维辛或DEM预处理导致注射氯化汞后的第一小时内肾脏汞的净蓄积量显著降低。这两种预处理的主要作用发生在肾皮质,尽管用DEM预处理也导致外髓质外层条纹中汞的浓度显著降低。尽管用BSO预处理导致肾脏GSH含量降低,与DEM所致相当,但用BSO预处理对汞在肾脏中的处置没有显著影响。用阿西维辛、BSO或DEM预处理也导致可测量的还原型GSH显著降低,其中BSO和DEM的作用最为明显。用阿西维辛预处理后注射无毒剂量的氯化汞导致肝脏汞含量略有但显著降低。有趣的是,用BSO或DEM预处理实际上在注射氯化汞1小时后导致肝脏汞含量显著增加。我们推测这种效应是由于肝细胞将GSH的汞结合物输出到胆汁或血液中的能力减弱所致。本研究结果表明,GSH与DEM之间的结合反应导致肾脏GSH消耗,从而使无机汞在肾脏中的蓄积急性减少。然而,结果还表明,通过抑制GSH合成来消耗肾脏中的GSH水平并不会急性影响肾脏蓄积无机汞的能力。因此,似乎除了细胞内GSH状态外,其他因素在无机汞的肾脏蓄积/潴留中也起着重要作用。